Immatics (IMTX) Cash from Investing Activities (2019 - 2025)
Immatics' (IMTX) quarterly Cash from Investing Activities came in at -$33.7 million in Q4 2025, up 33.55% year-on-year from -$25.2 million in Q4 2024, and down 123.48% quarter-over-quarter from $143.4 million in Q3 2025.
Immatics (IMTX) Cash from Investing Activities (2019 - 2025) Analysis & Trends
Immatics has disclosed Cash from Investing Activities across 7 years of filings, most recently posting -$33.7 million for Q4 2025.
- Cash from Investing Activities for Q4 2025 came in at -$33.7 million, up 33.55% year-over-year; the trailing twelve-month figure through Dec 2025 was $231.7 million (up 240.78% YoY), and the FY2025 annual result was $231.4 million, up 242.08% from the prior year.
- Cash from Investing Activities came in at -$33.7 million for Q4 2025 at Immatics, down from $143.4 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $143.4 million in Q3 2025 to a low of -$262.7 million in Q1 2024.
- The 5-year median for Cash from Investing Activities is -$3.0 million (2023), against an average of -$8.7 million.
- Peak annual rise in Cash from Investing Activities reached 510.15% in 2024, while the deepest fall reached 6481.11% in 2024.
- Immatics' Cash from Investing Activities stood at -$2.1 million in 2021, then plunged by 4300.84% to -$92.0 million in 2022, then surged by 169.84% to $64.3 million in 2023, then plunged by 178.82% to -$50.7 million in 2024, then surged by 33.55% to -$33.7 million in 2025.
- The last three Cash from Investing Activities figures came in at -$33.7 million (Q4 2025), $143.4 million (Q3 2025), and $72.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Immatics | 14.67 Bn | 14.67 Bn | - | -33.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -33.66 Mn |
| Dec 31, 2025 | -33.66 Mn |
| Sep 30, 2025 | 143.39 Mn |
| Sep 30, 2025 | 143.39 Mn |
| Jun 30, 2025 | 72.73 Mn |
| Jun 30, 2025 | 72.73 Mn |
| Mar 31, 2025 | 49.24 Mn |
| Mar 31, 2025 | 49.24 Mn |
| Dec 31, 2024 | -50.66 Mn |
| Dec 31, 2024 | -50.66 Mn |
| Sep 30, 2024 | 73.59 Mn |
| Sep 30, 2024 | 73.59 Mn |
| Jun 30, 2024 | 75.19 Mn |
| Jun 30, 2024 | 75.19 Mn |
| Mar 31, 2024 | -262.70 Mn |
| Mar 31, 2024 | -262.70 Mn |
| Dec 31, 2023 | 64.27 Mn |
| Dec 31, 2023 | 64.27 Mn |
| Sep 30, 2023 | -76.82 Mn |
| Sep 30, 2023 | -76.82 Mn |